AstraZeneca inhaler lags GSK drug in lung disease trial

A new AstraZeneca inhaler for chronic lung disease has proved worse than a rival GlaxoSmithKline product in a clinical trial, a result AstraZeneca said was inconsistent with earlier findings.

from Reuters: Health https://ift.tt/2OVZuB4
via IFTTT

• Tweet
• Share
• Share
• Share
• Share